Abstract
The authors found that buspirone added to the treatment of 33 patients with obsessive-compulsive disorder who were refractory to the serotonin reuptake inhibitor fluvoxamine was no better than placebo in reducing obsessive-compulsive, depressive, or anxiety symptoms. This finding suggests that addition of buspirone to ongoing fluvoxamine therapy is not an effective treatment strategy for most patients with obsessive-compulsive disorder.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Anxiety Disorders / diagnosis
-
Anxiety Disorders / psychology
-
Buspirone / therapeutic use*
-
Depressive Disorder / diagnosis
-
Depressive Disorder / psychology
-
Double-Blind Method
-
Drug Therapy, Combination
-
Female
-
Fluvoxamine / therapeutic use*
-
Humans
-
Male
-
Obsessive-Compulsive Disorder / drug therapy*
-
Obsessive-Compulsive Disorder / psychology
-
Placebos
-
Psychiatric Status Rating Scales
Substances
-
Placebos
-
Fluvoxamine
-
Buspirone